Walid Younis, MD
Pulmonary Disease · Hattiesburg, MSNPI 1619018983
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,952 of the $14,548 with a category attached, or 89.0%. It is spread thinly across 51 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations.
Across 749 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$2K
- Intuitive Surgical$2K
- Boehringer Ingelheim$782
- Mylan Specialty L.p.$683
- Grifols USA, LLC$655
- plus $6K from 45 others
What the payments were for
- Food & beverage$12,95289%
- Education$1,59611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,548 in reported general payments places this provider in the 80th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 72 | $749,637 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 518 | $393,906 |
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $163,776 |
| Breo ElliptaFluticasone/Vilanterol | 289 | $128,742 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 142 | $114,877 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 203 | $113,653 |
| EsbrietPirfenidone | 12 | $108,841 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 190 | $100,130 |
| Spiriva RespimatTiotropium Bromide | 83 | $57,017 |
| SymbicortBudesonide/Formoterol Fumarate | 136 | $49,870 |
| Pirfenidone | 21 | $40,715 |
| XareltoRivaroxaban | 39 | $32,309 |
| Ambrisentan | 11 | $31,350 |
| EliquisApixaban | 16 | $16,676 |
| Spiriva HandihalerTiotropium Bromide | 32 | $16,094 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $782 | $932,610377 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $2,893 | $642,2581,059 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,923 | $164,747278 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $86 | $163,77613 claims |
| Genentech USA, Inc.Esbriet | $151 | $108,84112 claims |
| Johnson & JohnsonXarelto | $172 | $32,30939 claims |
| PfizerEliquis | $43 | $16,67616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Hattiesburg
- L AldredHattiesburg$76K
- Tamer HudaliHattiesburg$15K
- Michael RaggioHattiesburg$11K
- Lewis NeeseHattiesburg$9K
- Kevin KinlochHattiesburg$6K
- Randolph RossHattiesburg$5K
- Charles McCollumHattiesburg$4K
- Andrew RognessHattiesburg$4K
- William FrazierCanton$809K
- Demondes HaynesJackson$809K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.